{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T20:30:12Z","timestamp":1794774612980,"version":"4.9.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"DOI":"10.1186\/s13195-025-01826-3","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T08:15:49Z","timestamp":1754554549000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Plasma phosphorylated tau 217 and amyloid\u2011\u03b2 42\/40 for amyloid risk in subgroups"],"prefix":"10.1186","volume":"17","author":[{"given":"Heekyoung","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heejin","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jungah","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soyeon","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Gonzalez-Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Ashton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa A.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Hoon","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihwan","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Young","family":"Chun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Hye","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Pyo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duk L.","family":"Na","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyemin","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daeun","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Won","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the K-ROAD study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,7]]},"reference":[{"key":"1826_CR1","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"J Hardy","year":"2002","unstructured":"Hardy J, Selkoe DJ. The amyloid hypothesis of alzheimer\u2019s disease: progress and problems on the road to therapeutics. Science. 2002;297:353\u20136. https:\/\/doi.org\/10.1126\/science.1072994.","journal-title":"Science"},{"key":"1826_CR2","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1002\/alz.12518","volume":"18","author":"SR Saroja","year":"2022","unstructured":"Saroja SR, Sharma A, Hof PR, et al. Differential expression of Tau species and the association with cognitive decline and synaptic loss in alzheimer\u2019s disease. Alzheimers Dement. 2022;18:1602\u201315. https:\/\/doi.org\/10.1002\/alz.12518.","journal-title":"Alzheimers Dement"},{"key":"1826_CR3","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early symptomatic alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330:512\u201327. https:\/\/doi.org\/10.1001\/jama.2023.13239.","journal-title":"JAMA"},{"key":"1826_CR4","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/ana.22608","volume":"70","author":"AG Vlassenko","year":"2011","unstructured":"Vlassenko AG, Mintun MA, Xiong C, et al. Amyloid-beta plaque growth in cognitively normal adults: longitudinal [11\u00a0C]Pittsburgh compound B data. Ann Neurol. 2011;70:857\u201361. https:\/\/doi.org\/10.1002\/ana.22608.","journal-title":"Ann Neurol"},{"key":"1826_CR5","doi-asserted-by":"publisher","first-page":"S633","DOI":"10.3233\/JAD-179928","volume":"64","author":"EC Mormino","year":"2018","unstructured":"Mormino EC, Papp KV. Amyloid accumulation and cognitive decline in clinically normal older individuals: implications for aging and early alzheimer\u2019s disease. J Alzheimers Dis. 2018;64:S633\u201346. https:\/\/doi.org\/10.3233\/JAD-179928.","journal-title":"J Alzheimers Dis"},{"key":"1826_CR6","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1212\/WNL.0000000000001991","volume":"85","author":"S Palmqvist","year":"2015","unstructured":"Palmqvist S, Zetterberg H, Mattsson N, et al. Detailed comparison of amyloid PET and CSF biomarkers for identifying early alzheimer disease. Neurology. 2015;85:1240\u20139. https:\/\/doi.org\/10.1212\/WNL.0000000000001991.","journal-title":"Neurology"},{"key":"1826_CR7","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.jalz.2018.01.010","volume":"14","author":"O Hansson","year":"2018","unstructured":"Hansson O, Seibyl J, Stomrud E, et al. CSF biomarkers of alzheimer\u2019s disease concord with amyloid-\u03b2 PET and predict clinical progression: a study of fully automated immunoassays in biofinder and ADNI cohorts. Alzheimers Dement. 2018;14:1470\u201381. https:\/\/doi.org\/10.1016\/j.jalz.2018.01.010.","journal-title":"Alzheimers Dement"},{"key":"1826_CR8","doi-asserted-by":"publisher","first-page":"729","DOI":"10.3233\/JAD-150066","volume":"47","author":"TL Michaud","year":"2015","unstructured":"Michaud TL, Kane RL, McCarten JR, et al. Risk stratification using cerebrospinal fluid biomarkers in patients with mild cognitive impairment: an exploratory analysis. J Alzheimers Dis. 2015;47:729\u201340. https:\/\/doi.org\/10.3233\/JAD-150066.","journal-title":"J Alzheimers Dis"},{"key":"1826_CR9","doi-asserted-by":"publisher","first-page":"e12921","DOI":"10.15252\/emmm.202012921","volume":"12","author":"M Suarez-Calvet","year":"2020","unstructured":"Suarez-Calvet M, Karikari TK, Ashton NJ, et al. Novel Tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical alzheimer\u2019s continuum when only subtle changes in Abeta pathology are detected. EMBO Mol Med. 2020;12:e12921. https:\/\/doi.org\/10.15252\/emmm.202012921.","journal-title":"EMBO Mol Med"},{"key":"1826_CR10","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","volume":"554","author":"A Nakamura","year":"2018","unstructured":"Nakamura A, Kaneko N, Villemagne VL, et al. High performance plasma amyloid-beta biomarkers for alzheimer\u2019s disease. Nature. 2018;554:249\u201354. https:\/\/doi.org\/10.1038\/nature25456.","journal-title":"Nature"},{"key":"1826_CR11","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr","year":"2024","unstructured":"Jack CR Jr., Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of alzheimer\u2019s disease: alzheimer\u2019s association workgroup. Alzheimers Dement. 2024;20:5143\u201369. https:\/\/doi.org\/10.1002\/alz.13859.","journal-title":"Alzheimers Dement"},{"key":"1826_CR12","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/s41591-024-02869-z","volume":"30","author":"NR Barthelemy","year":"2024","unstructured":"Barthelemy NR, Salvado G, Schindler SE, et al. Highly accurate blood test for alzheimer\u2019s disease is similar or superior to clinical cerebrospinal fluid tests. Nat Med. 2024;30:1085\u201395. https:\/\/doi.org\/10.1038\/s41591-024-02869-z.","journal-title":"Nat Med"},{"key":"1826_CR13","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","volume":"81","author":"NJ Ashton","year":"2024","unstructured":"Ashton NJ, Brum WS, Di Molfetta G, et al. Diagnostic accuracy of a plasma phosphorylated Tau 217 immunoassay for alzheimer disease pathology. JAMA Neurol. 2024;81:255\u201363. https:\/\/doi.org\/10.1001\/jamaneurol.2023.5319.","journal-title":"JAMA Neurol"},{"key":"1826_CR14","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s13195-024-01555-z","volume":"16","author":"AH Dyer","year":"2024","unstructured":"Dyer AH, Dolphin H, O\u2019Connor A, et al. Performance of plasma p-tau217 for the detection of amyloid-\u03b2 positivity in a memory clinic cohort using an electrochemiluminescence immunoassay. Alzheimers Res Ther. 2024;16:186. https:\/\/doi.org\/10.1186\/s13195-024-01555-z.","journal-title":"Alzheimers Res Ther"},{"key":"1826_CR15","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.14283\/jpad.2024.152","volume":"11","author":"F Mart\u00ednez-Dubarbie","year":"2024","unstructured":"Mart\u00ednez-Dubarbie F, Guerra-Ruiz A, L\u00f3pez-Garc\u00eda S, et al. Diagnostic accuracy of plasma p-tau217 for detecting pathological cerebrospinal fluid changes in cognitively unimpaired subjects using the lumipulse platform. J Prev Alzheimers Dis. 2024;11:1581\u201391. https:\/\/doi.org\/10.14283\/jpad.2024.152.","journal-title":"J Prev Alzheimers Dis"},{"key":"1826_CR16","doi-asserted-by":"publisher","first-page":"105046","DOI":"10.1016\/j.ebiom.2024.105046","volume":"102","author":"J Therriault","year":"2024","unstructured":"Therriault J, et al. Comparison of two plasma p-tau217 assays to detect and monitor alzheimer\u2019s pathology. eBioMedicine. 2024;102:105046.","journal-title":"eBioMedicine"},{"key":"1826_CR17","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1038\/s41591-022-02074-w","volume":"28","author":"NJ Ashton","year":"2022","unstructured":"Ashton NJ, Janelidze S, Mattsson-Carlgren N, et al. Differential roles of A\u03b242\/40, p-tau231 and p-tau217 for alzheimer\u2019s trial selection and disease monitoring. Nat Med. 2022;28:2555\u201362. https:\/\/doi.org\/10.1038\/s41591-022-02074-w.","journal-title":"Nat Med"},{"key":"1826_CR18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.14283\/jpad.2018.41","volume":"6","author":"V P\u00e9rez-Grijalba","year":"2019","unstructured":"P\u00e9rez-Grijalba V, Romero J, Pesini P, et al. Plasma A\u03b242\/40 ratio detects early stages of alzheimer\u2019s disease and correlates with CSF and neuroimaging biomarkers in the AB255 study. J Prev Alzheimers Dis. 2019;6:34\u201341. https:\/\/doi.org\/10.14283\/jpad.2018.41.","journal-title":"J Prev Alzheimers Dis"},{"key":"1826_CR19","doi-asserted-by":"publisher","first-page":"495","DOI":"10.3233\/JAD-220673","volume":"90","author":"C Xu","year":"2022","unstructured":"Xu C, Zhao L, Dong C. A review of application of A\u03b242\/40 ratio in diagnosis and prognosis of alzheimer\u2019s disease. J Alzheimers Dis. 2022;90:495\u2013512. https:\/\/doi.org\/10.3233\/JAD-220673.","journal-title":"J Alzheimers Dis"},{"key":"1826_CR20","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1001\/jamaneurol.2019.1534","volume":"76","author":"C Bridel","year":"2019","unstructured":"Bridel C, et al. Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis. JAMA Neurol. 2019;76:1035\u201348.","journal-title":"JAMA Neurol"},{"key":"1826_CR21","doi-asserted-by":"publisher","first-page":"e14526","DOI":"10.1002\/alz.14526","volume":"21","author":"H Jang","year":"2025","unstructured":"Jang H, et al. Differential roles of alzheimer\u2019s disease plasma biomarkers in Stepwise biomarker-guided diagnostics. Alzheimers Dement. 2025;21:e14526.","journal-title":"Alzheimers Dement"},{"key":"1826_CR22","doi-asserted-by":"publisher","first-page":"4094","DOI":"10.1093\/brain\/awae211","volume":"147","author":"DE Peretti","year":"2024","unstructured":"Peretti DE, Boccalini C, Ribaldi F, et al. Association of glial fibrillary acidic protein, alzheimer\u2019s disease pathology, and cognitive decline. Brain. 2024;147:4094\u2013104. https:\/\/doi.org\/10.1093\/brain\/awae211.","journal-title":"Brain"},{"key":"1826_CR23","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1001\/jamaneurol.2021.3671","volume":"78","author":"AL Benedet","year":"2021","unstructured":"Benedet AL, Mil\u00e0-Alom\u00e0 M, Vrillon A, et al. Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the alzheimer disease continuum. JAMA Neurol. 2021;78:1471\u201383.","journal-title":"JAMA Neurol"},{"key":"1826_CR24","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s10072-023-07065-4","volume":"45","author":"S Mazzeo","year":"2024","unstructured":"Mazzeo S, Ingannato A, Giacomucci G, et al. The role of plasma neurofilament light chain and glial fibrillary acidic protein in subjective cognitive decline and mild cognitive impairment. Neurol Sci. 2024;45:1031\u20139. https:\/\/doi.org\/10.1007\/s10072-023-07065-4.","journal-title":"Neurol Sci"},{"key":"1826_CR25","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","volume":"74","author":"N Mattsson","year":"2017","unstructured":"Mattsson N, Andreasson U, Zetterberg H, Blennow K. Association of plasma neurofilament light with neurodegeneration in patients with alzheimer disease. JAMA Neurol. 2017;74:557\u201366.","journal-title":"JAMA Neurol"},{"key":"1826_CR26","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1001\/jamaneurol.2019.0765","volume":"76","author":"N Mattsson","year":"2019","unstructured":"Mattsson N, Cullen NC, Andreasson U, et al. Association between longitudinal plasma neurofilament light and neurodegeneration in patients with alzheimer disease. JAMA Neurol. 2019;76:791\u20139. https:\/\/doi.org\/10.1001\/jamaneurol.2019.0765.","journal-title":"JAMA Neurol"},{"key":"1826_CR27","doi-asserted-by":"publisher","first-page":"8074","DOI":"10.1002\/alz.14315","volume":"20","author":"SE Schindler","year":"2024","unstructured":"Schindler SE, Petersen KK, Saef B, et al. Head-to-head comparison of leading blood tests for alzheimer\u2019s disease pathology. Alzheimers Dement. 2024;20:8074\u201396. https:\/\/doi.org\/10.1002\/alz.14315.","journal-title":"Alzheimers Dement"},{"key":"1826_CR28","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1002\/alz.13764","volume":"20","author":"MR Meyer","year":"2024","unstructured":"Meyer MR, Kirmess KM, Eastwood S, et al. Clinical validation of the PrecivityAD2 blood test: a mass spectrometry-based test with algorithm combining %p-tau217 and A\u03b242\/40 ratio to identify presence of brain amyloid. Alzheimers Dement. 2024;20:3179\u201392. https:\/\/doi.org\/10.1002\/alz.13764.","journal-title":"Alzheimers Dement"},{"key":"1826_CR29","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1001\/jamaneurol.2024.2619","volume":"81","author":"S Janelidze","year":"2024","unstructured":"Janelidze S, Barth\u00e9lemy NR, Salvad\u00f3 G, et al. Plasma phosphorylated Tau 217 and A\u03b242\/40 to predict early brain A\u03b2 accumulation in people without cognitive impairment. JAMA Neurol. 2024;81:947\u201357. https:\/\/doi.org\/10.1001\/jamaneurol.2024.2619.","journal-title":"JAMA Neurol"},{"key":"1826_CR30","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/alz.12395","volume":"18","author":"S Janelidze","year":"2022","unstructured":"Janelidze S, Palmqvist S, Leuzy A, et al. Detecting amyloid positivity in early alzheimer\u2019s disease using combinations of plasma A\u03b242\/A\u03b240 and p-tau. Alzheimers Dement. 2022;18:283\u201393. https:\/\/doi.org\/10.1002\/alz.12395.","journal-title":"Alzheimers Dement"},{"key":"1826_CR31","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1002\/alz.13542","volume":"20","author":"RA Rissman","year":"2024","unstructured":"Rissman RA, Langford O, Raman R, et al. Plasma A\u03b242\/A\u03b240 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical alzheimer\u2019s disease. Alzheimers Dement. 2024;20:1214\u201324. https:\/\/doi.org\/10.1002\/alz.13542.","journal-title":"Alzheimers Dement"},{"key":"1826_CR32","doi-asserted-by":"publisher","first-page":"823","DOI":"10.14283\/jpad.2024.134","volume":"11","author":"RA Rissman","year":"2024","unstructured":"Rissman RA, Donohue MC, Langford O, et al. Longitudinal phospho-tau217 predicts amyloid positron emission tomography in asymptomatic alzheimer\u2019s disease. J Prev Alzheimers Dis. 2024;11:823\u201330.","journal-title":"J Prev Alzheimers Dis"},{"key":"1826_CR33","doi-asserted-by":"publisher","first-page":"1320653","DOI":"10.3389\/fneur.2024.1320653","volume":"15","author":"T Fang","year":"2024","unstructured":"Fang T, Dai Y, Hu X, et al. Evaluation of serum neurofilament light chain and glial fibrillary acidic protein in the diagnosis of alzheimer\u2019s disease. Front Neurol. 2024;15:1320653. https:\/\/doi.org\/10.3389\/fneur.2024.1320653.","journal-title":"Front Neurol"},{"key":"1826_CR34","doi-asserted-by":"publisher","first-page":"1069411","DOI":"10.3389\/fneur.2023.1069411","volume":"14","author":"P Kivis\u00e4kk","year":"2023","unstructured":"Kivis\u00e4kk P, Carlyle BC, Sweeney T, et al. Plasma biomarkers for diagnosis of alzheimer\u2019s disease and prediction of cognitive decline in individuals with mild cognitive impairment. Front Neurol. 2023;14:1069411. https:\/\/doi.org\/10.3389\/fneur.2023.1069411.","journal-title":"Front Neurol"},{"key":"1826_CR35","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1002\/alz.12787","volume":"19","author":"A Pichet Binette","year":"2023","unstructured":"Pichet Binette A, Janelidze S, Cullen N, et al. Confounding factors of alzheimer\u2019s disease plasma biomarkers and their impact on clinical performance. Alzheimers Dement. 2023;19:1403\u201314. https:\/\/doi.org\/10.1002\/alz.12787.","journal-title":"Alzheimers Dement"},{"key":"1826_CR36","doi-asserted-by":"publisher","unstructured":"Lee EH, Kang SH, Shin D et al. Plasma Alzheimer\u2019s disease biomarker variability: amyloid-independent and amyloid-dependent factors. Alzheimers Dement. 2024;:. https:\/\/doi.org\/10.1002\/alz.14368","DOI":"10.1002\/alz.14368"},{"key":"1826_CR37","doi-asserted-by":"publisher","first-page":"1126799","DOI":"10.3389\/fnagi.2023.1126799","volume":"15","author":"MY Chun","year":"2023","unstructured":"Chun MY, Jang H, Kim HJ, et al. Contribution of clinical information to the predictive performance of plasma beta-amyloid levels for amyloid positron emission tomography positivity. Front Aging Neurosci. 2023;15:1126799. https:\/\/doi.org\/10.3389\/fnagi.2023.1126799.","journal-title":"Front Aging Neurosci"},{"key":"1826_CR38","doi-asserted-by":"publisher","first-page":"212","DOI":"10.12779\/dnd.2024.23.4.212","volume":"23","author":"H Jang","year":"2024","unstructured":"Jang H, Shin D, Kim Y, et al. Korea-Registries to overcome dementia and accelerate dementia research (K-ROAD): a cohort for dementia research and ethnic-specific insights. Dement Neurocogn Disord. 2024;23:212\u201323. https:\/\/doi.org\/10.12779\/dnd.2024.23.4.212.","journal-title":"Dement Neurocogn Disord"},{"issue":"3","key":"1826_CR39","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s association workgroups on diagnostic guidelines for alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):270\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.008.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"1826_CR40","doi-asserted-by":"publisher","first-page":"117","DOI":"10.12779\/dnd.2024.23.3.117","volume":"23","author":"J Kim","year":"2024","unstructured":"Kim J, Jahng S, Kim S, et al. A comparison of item characteristics and test information between the K-MMSE\u2009~\u20092:SV and K-MMSE. Dement Neurocogn Disord. 2024;23(3):117\u201326. https:\/\/doi.org\/10.12779\/dnd.2024.23.3.117.","journal-title":"Dement Neurocogn Disord"},{"issue":"1","key":"1826_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12779\/dnd.2023.22.1.1","volume":"22","author":"HJ Ryu","year":"2023","unstructured":"Ryu HJ, Yang DW. The Seoul neuropsychological screening battery (SNSB) for comprehensive neuropsychological assessment. Dement Neurocogn Disord. 2023;22(1):1\u201315. https:\/\/doi.org\/10.12779\/dnd.2023.22.1.1.","journal-title":"Dement Neurocogn Disord"},{"key":"1826_CR42","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1007\/s00259-019-04596-x","volume":"47","author":"SH Cho","year":"2020","unstructured":"Cho SH, et al. A new centiloid method for (18)F-florbetaben and (18)F-flutemetamol PET without conversion to PiB. Eur J Nucl Med Mol Imaging. 2020;47:1938\u201348.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1826_CR43","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1212\/WNL.0000000000007747","volume":"93","author":"GN Bischof","year":"2019","unstructured":"Bischof GN, et al. Subthreshold amyloid and its biological and clinical meaning. Neurology. 2019;93:72\u20139.","journal-title":"Neurology"},{"key":"1826_CR44","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13195-020-00587-5","volume":"12","author":"S Amadoru","year":"2020","unstructured":"Amadoru S, et al. Comparison of amyloid PET measured in centiloid units with neuropathological findings in alzheimer\u2019s disease. Alzheimers Res Ther. 2020;12:22.","journal-title":"Alzheimers Res Ther"},{"key":"1826_CR45","doi-asserted-by":"publisher","unstructured":"Ahn J, Lee EH, Yoo H, et al. Tailoring thresholds for interpreting plasma p-tau217 levels. J Neurol Neurosurg Psychiatry. 2025 May;24. https:\/\/doi.org\/10.1136\/jnnp-2025-335830.","DOI":"10.1136\/jnnp-2025-335830"},{"key":"1826_CR46","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13195-024-01469-w","volume":"16","author":"Y Niimi","year":"2024","unstructured":"Niimi Y, Janelidze S, Sato K, et al. Combining plasma A\u03b2 and p-tau217 improves detection of brain amyloid in non-demented elderly. Alzheimers Res Ther. 2024;16:115. https:\/\/doi.org\/10.1186\/s13195-024-01469-w.","journal-title":"Alzheimers Res Ther"},{"key":"1826_CR47","unstructured":"De Simone FI et al. Clinical performance of the Lumipulse G pTau 217\/\u03b2-amyloid 1\u201342 plasma ratio. Presented at the 17th Clinical Trials on Alzheimer\u2019s Disease Congress, Madrid, Spain, 2024."},{"key":"1826_CR48","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1016\/S2666-7568(20)30061-1","volume":"2","author":"IMW Verberk","year":"2021","unstructured":"Verberk IMW, Laarhuis MB, van den Bosch KA, et al. Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study. Lancet Healthy Longev. 2021;2:e87\u201395. https:\/\/doi.org\/10.1016\/S2666-7568(20)30061-1.","journal-title":"Lancet Healthy Longev"},{"key":"1826_CR49","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","volume":"74","author":"N Mattsson","year":"2017","unstructured":"Mattsson N, Andreasson U, Zetterberg H, Blennow K, Alzheimer\u2019s Disease Neuroimaging Initiative. Association of plasma neurofilament light with neurodegeneration in patients with alzheimer disease. JAMA Neurol. 2017;74:557\u201366. https:\/\/doi.org\/10.1001\/jamaneurol.2016.6117.","journal-title":"JAMA Neurol"},{"key":"1826_CR50","doi-asserted-by":"publisher","first-page":"101077","DOI":"10.1016\/j.lanepe.2024.101077","volume":"45","author":"J Contador","year":"2024","unstructured":"Contador J, Su\u00e1rez-Calvet M. Blood-based biomarkers in the oldest old: towards alzheimer\u2019s disease detection in primary care. Lancet Reg Health Eur. 2024;45:101077. https:\/\/doi.org\/10.1016\/j.lanepe.2024.101077.","journal-title":"Lancet Reg Health Eur"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01826-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-025-01826-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01826-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T22:34:23Z","timestamp":1757370863000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-025-01826-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1826"],"URL":"https:\/\/doi.org\/10.1186\/s13195-025-01826-3","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,7]]},"assertion":[{"value":"9 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The institutional review board of Samsung Medical Center (No. 2021-02-135) approved this study. All participants provided informed consent to participate in the study, and the data were collected in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Henrik Zetterberg has served on scientific advisory boards and\/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave. He has delivered lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, and Roche. He is also a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is part of the GU Ventures Incubator Program (outside the submitted work). Kaj Blennow has served as a consultant and advisory board member for Abbvie, AC Immune, ALZPath, AriBio, BioArctic, Biogen, Eisai, Lilly, Moleac Pte. Ltd, Novartis, Ono Pharma, Prothena, Roche Diagnostics, and Siemens Healthineers. He has served on data monitoring committees for Julius Clinical and Novartis. He has also delivered lectures, produced educational materials, and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai, and Roche Diagnostics. Additionally, he is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is part of the GU Ventures Incubator Program, outside the work presented in this paper. All other authors declare no conflicts of interest. Theresa A. Day is an employee and minor stockholder of Eli Lilly and Company.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"184"}}